A Study on the Clinical Profile and Pharmacogenetics of Methotrexate Treatment in Patients with Rheumatoid Arthritis
April 2014
TLDR The 1298CC genotype in RA patients leads to higher methotrexate toxicity, while the 1298AA genotype results in better treatment response.
The study investigated the MTHFR A1298C polymorphism's impact on methotrexate (MTX) efficacy and toxicity in 100 Indian rheumatoid arthritis (RA) patients, with 42 completing the study. It found that the 1298CC genotype was more common in RA patients and associated with higher toxicity, including elevated transaminases and gastrointestinal issues, despite folate supplementation. Conversely, the 1298AA genotype was linked to better treatment response and lower toxicity. The study highlighted the importance of pharmacogenetics in predicting treatment outcomes and suggested that larger sample sizes and further genetic analyses could improve clinical management of RA.